Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00917956 · ClinicalTrials.gov registry record

Lithium in Inclusion Body Myositis (IBM)

A clinical trial of Inclusion Body Myositis, sponsored by Phoenix Neurological Associates.

Completed
Registry status
20
Enrollment target
1
Study location

NCT00917956 is a study of Inclusion Body Myositis that has completed, run by Phoenix Neurological Associates. The registered enrollment target is 20 participants, below the 234-participant average among 10 other Inclusion Body Myositis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00917956, a study of Inclusion Body Myositis, has completed, sponsored by Phoenix Neurological Associates.

COMPLETED
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

IBM is the most common acquired muscle disease occurring over the age of 50. The underlying cause remains unknown and there is currently no effective treatment. Pathological studies have revealed abnormal collections of proteins in the muscle cells from patients with IBM. These include proteins called phosphorylated tau (p-tau). A similar process appears to occur in Alzheimer disease, with accumulations of p-tau developing in brain cells. Lithium decreases the activity of the GSK, an enzyme that has a key role in the development of p-tau. Lithium and other GSK inhibitors have been shown to decrease the accumulation of p-tau in nerve cells in animal models of Alzheimer disease. The proposed research is a pilot study to see if lithium might be an effective treatment for IBM

Conditions Studied

Study Locations (1)

Arizona

  • Phoenix Neurological Associates, LTD - Phoenix

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-06
Est. Completion 2009-12

Sponsor

Phoenix Neurological Associates

4 total trials

What the Registry Record Tells You About NCT00917956

The ClinicalTrials.gov registry entry for NCT00917956 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 234-participant average among 10 other Inclusion Body Myositis trials with a reported enrollment target (91% lower). The listed sponsor is Phoenix Neurological Associates, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Inclusion Body Myositis appearing as the primary indexed condition, and to 0 interventions.

NCT00917956 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT00917956 about?

NCT00917956 is a clinical study titled "Lithium in Inclusion Body Myositis (IBM)". IBM is the most common acquired muscle disease occurring over the age of 50. The underlying cause remains unknown and there is currently no effective treatment. Pathological studies have revealed abnormal collections of proteins in the muscle cells from patients with IBM. These include proteins call...

What is the current status of trial NCT00917956?

This trial is currently completed. The enrollment target is 20 participants. The study started on 2008-06. Estimated completion is 2009-12.

What conditions does trial NCT00917956 study?

This clinical trial studies the following conditions: Inclusion Body Myositis.

Who is sponsoring clinical trial NCT00917956?

This trial is sponsored by Phoenix Neurological Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00917956 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inclusion Body Myositis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.